Related Experiment Video
Updated: May 4, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
NSAID ulcers: prevalence and prevention
1Rm 3A-320 (111D), Veterans Affairs Medical Center , 2002 Holcombe Blvd., Houston, TX 77030 , USA.
Abstract:
Abstract The epidemic of life-threatening complications of nonsteroidal anti-inflammatory drug (NSAID) use has prompted the development of prevention strategies. Recent clinical trials of endoscopic ulcer prevention are critiqued regarding their results in relation to doses and outcome measures as well as H. pylori status. Misoprostol is the only agent proven to prevent life-threatening ulcer complication in NSAID users. Proton pump inhibitor therapy was not significantly better than the minimally effective dose of misoprostol for prevention of gastroduodenal ulcers in chronic NSAID users, and was significantly inferior to misoprostol in those with "true" NSAID ulcers (i.e., without complicating H. pylori infection). Antisecretory therapy accelerates corpus gastritis in those with H. pylori infection, suggesting it is prudent to consider H. pylori eradication in those in whom long term co-therapy with anti-secretory therapy is contemplated. H. pylori status is a critical variable with regard to endoscopic ulcers in NSAID users. The data suggest that if full-dose misoprostol cannot be given, the combination of an antisecretory drug (e.g., either ranitidine or omeprazole) plus low-dose misoprostol may be better than either alone for the prevention of NSAID ulcer complications. The use of omeprazole alone likely results in a false sense of security.
Insights
Misoprostol is the only proven agent to prevent serious ulcers from nonsteroidal anti-inflammatory drug (NSAID) use. Combining proton pump inhibitors with misoprostol may offer better ulcer prevention than either alone in NSAID users.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used but associated with serious gastrointestinal complications, including ulcers.
- Effective prevention strategies for NSAID-induced ulcers are crucial due to their epidemic nature.
Purpose of the Study:
- To critique recent clinical trials on endoscopic ulcer prevention in NSAID users.
- To evaluate the efficacy of different agents and H. pylori status in preventing NSAID-related gastroduodenal ulcers.
Main Methods:
- Review and critique of results from clinical trials on endoscopic ulcer prevention.
- Analysis of outcomes based on drug doses, outcome measures, and Helicobacter pylori (H. pylori) status.
Main Results:
- Misoprostol is the only agent definitively proven to prevent life-threatening ulcer complications in NSAID users.
- Proton pump inhibitor (PPI) therapy was not superior to a low dose of misoprostol for gastroduodenal ulcer prevention in chronic NSAID users.
- PPIs were significantly inferior to misoprostol in patients with H. pylori-negative ulcers, while antisecretory therapy accelerated gastritis in H. pylori-positive patients.
- Combination therapy with an antisecretory drug and low-dose misoprostol may be more effective than monotherapy for preventing NSAID ulcer complications.
Conclusions:
- H. pylori status is a critical factor in managing NSAID-induced ulcers.
- Consideration of H. pylori eradication is prudent for patients requiring long-term co-therapy with antisecretory agents.
- Omeprazole alone may provide a false sense of security regarding NSAID ulcer prevention.
More Related Videos
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:24Peptic Ulcer Disease II: Pathophysiology
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:25Peptic Ulcer Disease I: Introduction
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...